ImmunityBio, Inc. Common Stock (IBRX) Stock Price
IBRXStock
$9.18+262.85%52W
Market Cap$9.73B
P/E—
PEG Ratio—
Div yield—
Beta0.18
IBRX Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)10.88%
Price vs S&P 500 (4W)9.96%
VGM Score61.78
IBRX Earnings Surprise History
| Quarter | Report date | EPS estimate | EPS actual | Surprise |
|---|---|---|---|---|
| Q2 2026 | -$0.08 | -$0.22 | -175.00%(-$0.14) | |
| Q1 2026 | -$0.07 | -$0.08 | -20.00%(-$0.01) | |
| Q4 2025 | -$0.10 | -$0.06 | +37.93%(+$0.04) | |
| Q3 2025 | -$0.10 | -$0.07 | +30.00%(+$0.03) | |
| Q2 2025 | -$0.10 | -$0.10 | +0.00%(+$0.00) |
IBRX Analyst Recommendations
Jun 2026
Jul 2026
Aug 2026
Sep 2026
4.30
4.30
4.30
4.30
Industry Peers — Biological Products(186)
| Symbol | Value Score | Growth Score | Momentum Score | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|---|---|---|
IBRXImmunityBio, Inc. Common Stock | F | A | A | 58.7x | 192.9% | 99.3% | — | $9.18 |
| AMGNAmgen Inc | D | C | A | 6.1x | 9.1% | 74.3% | 2.9% | $432.49 |
| GILDGilead Sciences Inc | C | B | A | 6.4x | 5.5% | 79.6% | 133.6% | $156.19 |
| MRNAModerna, Inc. Common Stock | F | C | A | 39.1x | -27.6% | 36.4% | — | $218.01 |
| ARGXargenx SE American Depositary Shares | D | A | B | 6.6x | 165.2% | 89.8% | — | $819.14 |
| RVMDRevolution Medicines, Inc. Common Stock | F | — | B | 3296.2x | — | — | — | $177.96 |
| BIIBBiogen Inc. Common Stock | C | D | A | 3.4x | 0.3% | 74.0% | -18.8% | $232.65 |
| BNTXBioNTech SE American Depositary Share | C | C | C | 7.6x | -11.8% | 79.2% | — | $87.71 |
| EXELExelixis Inc | C | B | A | 6.3x | 9.2% | 96.5% | 31.1% | $62.23 |
| HALOHalozyme Therapeutics, Inc. | D | B | A | 8.3x | 41.1% | 82.4% | 22.9% | $121.84 |
| NBIXNeurocrine Biosciences Inc | C | B | B | 4.1x | 34.4% | 98.0% | 2.3% | $135.71 |
About ImmunityBio, Inc. Common Stock
ImmunityBio develops immunotherapies for cancer and infectious diseases through its proprietary Cancer BioShield platform, which activates both adaptive and innate immune systems. The platform is anchored by ANKTIVA, an IL-15 superagonist, complemented by adenovirus-vectored vaccines and NK-cell therapies. The company generates the majority of its revenue in the United States, with additional operations in Europe.